a public good project by the
Synthesis
Company
of California

© 2026

John D. Haley | doi.page

0 works0 citations0 h-index

John D. Haley

Stony Brook Medicine(US)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Cancer, Hypoxia, and Metabolism, PI3K/AKT/mTOR signaling in cancer, RNA modifications and cancer

Most-Cited Works

→ Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition(2005)672 cited
→ Cloning of cDNA for a stylar glycoprotein associated with expression of self-incompatibility in Nicotiana alata(1986)500 cited
→ Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib(2006)439 cited
→ Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors(2006)233 cited
→ Structure of a genomic clone encoding biologically active human relaxin(1983)227 cited
→ A systems view of epithelial–mesenchymal transition signaling states(2010)211 cited

→ Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors(2008)

209 cited

→ Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions(2008)199 cited

→ Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy(2008)191 cited

→ Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition(2007)188 cited